Highlights from Innate Pharma's R&D update

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today holds an R&D update.

The key topics covered are:

• Innate Pharma’s corporate strategy and positioning in the immuno-oncology space
• Update on lirilumab clinical development
• IPH2201 scientific rationale and clinical development plan
• Financial update

The R&D Update is webcasted and also available after the event at the following link: http://psav.rampard.com/20140410/